Articles tagged with Lung Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A randomized Phase II trial shows that resecting the primary thoracic tumor after EGFR TKI therapy may prolong disease control in patients with metastatic EGFR-mutated non-small cell lung cancer. The study aims to extend the benefits of EGFR TKI beyond standard monotherapy by targeting residual disease through surgery.
A new study at WCLC demonstrates that monitoring circulating tumor DNA can refine and personalize the use of consolidation immunotherapy in patients with limited-stage small cell lung cancer. Early ctDNA detection after induction chemotherapy identifies patients more likely to benefit from consolidation immunotherapy.
A large-scale survey by Lung Cancer Europe identified critical communication barriers affecting information access and understanding among lung cancer patients and caregivers. The study found that complex medical language was a major obstacle to shared decision-making, with only 56% of respondents feeling their opinion was considered i...
A clinical trial found that patients with mesothelioma who received combination immunotherapy drugs before surgery had successful surgeries and improved early outcomes. The study showed that tracking tumor DNA in the blood could help predict treatment benefit.
The PALOMA-2 study found that subcutaneous amivantamab every 4 weeks, combined with daily oral lazertinib, yields a high objective response rate in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer. This dosing regimen offers fewer administration-related reactions and improved convenience for patients.
Emphysema detected on low-dose chest CT scans in asymptomatic adults increases mortality risk over a 25-year follow-up period. The study found that emphysema severity is associated with higher COPD and cardiovascular disease mortality rates, suggesting it as a distinct disease entity linked to poorer health outcomes.
Concurrent durvalumab therapy did not improve overall survival compared to consolidation alone in unresectable stage 3 NSCLC patients. The trial enrolled 662 patients and showed median OS was 41.5 months in the concurrent arm versus 39.4 months in the consolidation arm.
The NADIM ADJUVANT Phase III trial suggests that adding nivolumab to adjuvant chemotherapy can reduce recurrence risk and may offer meaningful clinical benefit for patients with completely resected stage IB–IIIA non-small cell lung cancer. The three-year relapse rate was 26.7% in the experimental arm versus 40.1% in the control arm.
A UK study found that lung cancer screening can benefit older adults up to age 80 who are eligible for surgery. The research, presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer, showed comparable survival rates between younger and older patients treated with surgery.
A phase III trial found hypofractionated radiotherapy (HypoRT) with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC). Patients receiving HypoRT experi...
The DeLLphi-303 trial demonstrates tarlatamab's safety and efficacy as a first-line maintenance treatment for ES-SCLC, with median OS of 25.3 months and PFS of 5.6 months. The combination also showed a manageable safety profile, with cytokine release syndrome being the most common adverse event.
A meta-analysis of randomized trials comparing video-assisted thoracoscopic surgery (VATS) and open lobectomy found a 21% reduced risk of death in VATS patients. The study also showed no difference in disease-free survival between the two groups.
The Phase 1CA240-0007 trial demonstrates a 29% overall response rate and 80% disease control rate for BMS-986504 in heavily pretreated patients with MTAP-deleted NSCLC. The agent selectively targets the PRMT5-MTA complex while sparing normal tissue.
The Phase 2 IDeate-Lung01 trial demonstrated a confirmed objective response rate of 48.2% and disease control rate of 87.6% in patients with recurrent or progressive ES-SCLC. Ifinatamab deruxtecan showed manageable safety and high response rates, supporting further investigation in small cell lung cancer.
A Phase 3 trial found that crizotinib did not prolong disease-free survival in patients with resected early-stage ALK+ NSCLC. The study included 166 patients and followed them for a median of 58.3 months.
The global Phase 3 HARMONi trial found that ivonescimab plus chemotherapy significantly prolonged progression-free survival (PFS) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. Median PFS was 6.8 months, and the overall response rate was higher in the ivonescimab group.
A Phase 1 study of SHR-4849 demonstrated early signs of anti-tumor activity in patients with relapsed small cell lung cancer, with an objective response rate of 59.5% and disease control rate of 90.5%. The drug showed manageable safety and favorable pharmacokinetics.
Zidesamtinib demonstrated clinically meaningful activity and durability in patients with ROS1-positive NSCLC who had progressed on prior TKI therapy. Durable responses were observed in patients with CNS involvement, ROS1 G2032R mutations, and multiple prior ROS1 TKIs.
The ACROSS 2 Phase III trial demonstrates that combining aumolertinib with platinum-pemetrexed chemotherapy significantly improves progression-free survival in patients with advanced/metastatic NSCLC harboring EGFR sensitizing mutations and concomitant tumor suppressor gene mutations. The treatment regimen showed a manageable safety pr...
The FLAURA2 trial shows osimertinib plus chemotherapy significantly improves overall survival compared to osimertinib monotherapy in patients with EGFR-mutated advanced NSCLC. The combination also demonstrates a manageable safety profile, extending survival for these patients.
A new study validates the use of Sybil, a deep learning artificial intelligence model, for predicting future lung cancer risk in a predominantly Black population. The model demonstrated high predictive accuracy for lung cancer risk up to six years after a single low-dose CT scan.
The COMPEL trial demonstrates that patients with EGFR-mutated advanced non-small cell lung cancer benefit from continued osimertinib treatment in combination with platinum-based chemotherapy. This approach is associated with improved progression-free survival and overall survival compared to placebo plus chemotherapy.
A novel antibody-drug conjugate iza-bren demonstrated an objective response rate of 66.0% and a confirmed ORR of 56.0% in EGFR-mutated NSCLC patients, with manageable safety profile. The median progression-free survival was 12.5 months.
The CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life in patients with resectable non-small cell lung cancer, including those with Stage III N2 disease. Nivolumab also reduces risk of symptom deterioration in these high-risk patients.
A combination of iza-bren and osimertinib demonstrated a 100% objective response rate in patients with first-line EGFR-mutated locally advanced or metastatic non-small cell lung cancer. The regimen was also manageable from a safety perspective, with most treatment-related adverse events being hematologic.
The ASTRO's 2025 Annual Meeting will feature pivotal studies in radiation medicine, highlighting advances in radiopharmaceutical therapy and new indications for low-dose radiation therapy. The meeting will also explore cutting-edge techniques for prostate, breast, lung, and other common cancers.
Researchers found a new variant of mesothelioma associated with inherited germline BAP1 mutations, which are less aggressive and may respond to therapy. These patients also develop multiple tumors and require early cancer detection screening.
Lung cancer subtypes differ in metabolic profiles, with metabolomics offering insights into subtype-specific alterations. Metabolomics enables effective subtype differentiation and identification of potential biomarkers for early diagnosis and personalized therapy.
A new guideline from the Canadian Task Force on Preventive Health Care provides a menu of effective options to help people quit smoking, including behavioural and medication options. The guideline aims to address the challenges of nicotine addiction and offers personalized choices for quitting tobacco.
A recent study published in Nature Communications provides a comprehensive characterization of Large Cell Neuroendocrine Carcinoma (LCNEC), a rare and aggressive type of lung cancer. The research team analyzed data from 590 patients and found that LCNEC shares features with other types of lung cancer, yet has distinct aspects. They ide...
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
A new web-based tool has been developed to provide tailored resources for states and local leaders to reduce lung cancer mortality rates. The tool addresses health equity and incorporates user feedback to offer recommendations based on regional needs.
A new multi-institutional study confirmed that the NSD2 protein can be targeted with a new drug, blocking it effectively reprogrammed DNA structure, reversed and prevented cancer growth in preclinical models of KRAS-mutant lung and pancreatic cancers. Targeting the brain-liver pathway with electronic wearables could prevent cancer-asso...
The symposium will feature talks by leading researchers on various aspects of cancer, including molecular discovery, clinical application, and population impact. Key findings include the exploration of genomic inequities and their impact on cancer disparities.
A new study in The American Journal of Pathology reveals that perilipin 2 protein modulates aggressive cancer progression in advanced lung adenocarcinoma by regulating lipid droplet accumulation. High perilipin 2 expression is associated with more aggressive disease progression and shorter recurrence-free survival times.
Researchers have developed a novel technology that can simultaneously silence two notoriously difficult-to-target cancer-related genes, KRAS and MYC. This innovation has the potential to treat cancers that have been challenging to treat, with significant implications for patients.
The study aims to create a path forward for improved treatment, access to clinical trials, and personalized care for communities with limited access to care. Recent studies highlight the need to address systemic barriers that prevent many people from receiving advanced care.
A higher intake of ultra-processed food is linked to an increased risk of lung cancer. Limiting UPF consumption may help reduce the global burden of the disease. Research found that participants in the highest quarter of energy-adjusted UPF consumption were 41% more likely to be diagnosed with lung cancer.
The American College of Chest Physicians has released a clinical guideline on the management of patients with early-stage non-small cell lung cancer. The guideline provides evidence-based recommendations for primary treatment and outlines three flowchart graphs outlining the recommended course of treatment based on patient risk. These ...
Researchers at Chongqing Medical University discovered NF-kappa-B-activating protein-like (NKAPL) acts as a tumor suppressor in non-small cell lung cancer by stabilizing TRIM21 and inhibiting NF-κB signaling. Restoration of NKAPL expression suppresses cancer progression, offering new diagnostic and therapeutic strategies.
Researchers have discovered a promising new approach to suppress the growth of aggressive cancers by targeting minor splicing, a specialized molecular process. By blocking minor splicing, cancer cells accumulate DNA damage and trigger cell death, while healthy cells remain largely unaffected.
Researchers found that standard DNA testing does not detect NUT carcinoma fusion genes in over 75% of patients. Additional tests like NUT immunohistochemistry and RNA fusion testing can reliably identify gene fusions, leading to more accurate diagnoses and potentially life-saving treatments.
A combination of two approved cancer medications may slow or reverse Alzheimer's symptoms by reversing gene expression changes in neurons and brain cells. Researchers analyzed public data from deceased donors and found a link between these drugs and reduced risk of developing the disease.
Researchers from Memorial Sloan Kettering Cancer Center developed a new approach to induce mutations in resistant cancer cells, making them sensitive to immunotherapy. The study showed positive outcomes in patients over 90 with lung cancer who underwent surgery.
A multidisciplinary guideline panel has determined that guided-bronchoscopy sampling provides tissue of comparable adequacy to percutaneous biopsy for comprehensive biomarker testing, while delivering a superior safety profile. Modern navigational bronchoscopy offers a safer path to molecular insights in lung cancer care.
Researchers at the University of Würzburg are developing a new therapy for KEAP1-mutated lung cancer using a sulfite inhibitor to block tumor cell growth. The team has identified a first-of-its-kind compound, SulfExstatin-1, which accumulates toxic sulfite in cancer cells, initiating their death.
Researchers at Mass General Brigham found that targeted radiation was successful in treating patients with brain metastases, resulting in a lower neurological death rate and reduced need for subsequent whole brain radiation. This study supports personalized treatment approaches to maintain quality of life while managing brain metastases.
A recent analysis of 16 years of data on Japanese adults reveals a strong association between socioeconomic status and the incidence of five common cancers. Communities with low employment rates or low incomes show higher cancer rates compared to those with higher socioeconomic status.
A new multi-institutional clinical trial will test zipalertinib, an investigational drug targeting specific EGFR mutations in early-stage non-small cell lung cancer. The goal is to prevent recurrence and improve long-term outcomes for patients with limited treatment options.
Researchers at Keck Medicine of USC found that high doses of corticosteroids can limit the effectiveness of immunotherapies in treating non-small cell lung cancer. Corticosteroids, commonly prescribed for symptom management, were shown to stop T-cells from maturing, reducing their ability to attack cancer cells.
A new study reveals that air pollution contributes to the development of lung cancer in people with no or hardly any history of smoking. The study found a strong association between air pollution and genetic mutations in lung tumors, particularly driver mutations that promote cancer development.
A whole-genome sequencing study found fine-particulate air pollution to cause more cancer-related changes than secondhand smoke. Researchers analyzed lung tumors from 871 never-smoker patients across 28 geographic locations worldwide and linked air pollution exposure to increased genomic changes.
Residential segregation contributes to lung cancer development in African Americans, highlighting the need for policymakers to address disparities. Structural racism in neighborhoods affects health outcomes, emphasizing the importance of reducing racial gaps in healthcare.
This study identifies pre-neadjuvant carcinoembryonic antigen (CEA) and neutrophil-to-lymphocyte ratio (NLR) as significant predictors of postoperative recurrence-free survival in non-small cell lung cancer (NSCLC) patients after neoadjuvant therapy. Smoking history is also a predictor of recurrence in LUSC patients.
A new study found diverse genetic patterns and treatment gaps in HER2-mutated non-small cell lung cancer (NSCLC) in Northeastern Brazil. The research highlights the importance of comprehensive molecular profiling and expanded access to targeted therapies for underrepresented populations.
A new dual-phase CT AI tool, NeoPred, combines pre-treatment and pre-surgery scans with clinical data to predict major pathological response in NSCLC patients. The model achieved high accuracy rates, including AUCs of 0.772-0.787, outperforming surgeons and improving diagnostic accuracy.
Researchers found that lung cancer patients with both high levels of depression and inflammation at diagnosis had increasing depressive symptoms over the next eight months. These patients showed no changes in depression when only having high levels of depression or only high levels of inflammation, or neither. The study suggests an add...
A study of 95 patients found that wrapping autologous tissue materials around anastomoses after airway reconstruction significantly reduced short-term postoperative complications. This technique may offer a positive effect on the prognosis of patients undergoing complex tracheobronchial resection and reconstruction.
A retrospective study found ESL to be a safe and viable alternative to pneumonectomy for selected patients with centrally located NSCLC. ESL offered better event-free survival compared to pneumonectomy.
A study of 203 patients shows that electromagnetic navigation bronchoscopy (ENBDM) is a safer and faster alternative to CT-guided localization for preoperative treatment of multiple pulmonary nodules in the same lung. ENBDM achieved comparable accuracy with lower complication rates, making it an optimal strategy.